DOI: 10.12890/2023_003908

The changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination

Authors

  • Elvis Matini Medical Oncology Department, Mercy University Hospital, Cork, T12 WE28, Ireland
  • Trishhani Yogaretnam Medical Oncology Department, Mercy University Hospital, Cork, T12 WE28, Ireland
  • Charlotte Alice Wilson Medical Oncology Department, Mercy University Hospital, Cork, T12 WE28, Ireland
  • Derek Power Medical Oncology Department, Mercy University Hospital, Cork, T12 WE28, Ireland

e-manz@hotmail.com

Keywords

Oligometastatic renal disease, Immunotherapy, Squamous NSCLC, Nephrectomy

Abstract

This report describes a rare case of oligometastatic renal disease in a 69 year-old Caucasian male with non-small cell lung cancer (NSCLC). Diagnosed with Stage IIIb, NSCLC he completed chemoradiotherapy followed by 1 year of immunotherapy. Surveillance CT scans after nearly three years showed an ill-defined lesion in the left kidney.
Biopsy results were consistent with metastasis from the known lung carcinoma. Following neo-adjuvant Pembrolizumab (200mg, q3w), the patient underwent a left radical nephrectomy, without complications. One year post-operatively, CT of the thorax, abdomen and pelvis (TAP) did not identify any recurrence.
Renal metastases were historically demonstrated predominantly by autopsy studies[1]. Any mass manifesting in the kidney in the context of previous NSCLC warrants comprehensive investigations. The combination of immunotherapy followed by definitive treatment appears to be a promising management strategy[2]. With regards to local curative options, the advantages and disadvantages of surgery and radiotherapy have been well described[3-4].

View the entire article

Downloads

References

  1. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, et al. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int 2016;117:775-782.
  2. Stefani D, Plönes T, Viehof J, Darwiche K, Stuschke M, Schuler M, et al. Lung Cancer Surgery after Neoadjuvant Immunotherapy. Cancers (Basel) 2021;13:4033.
  3. Tohme S, Simmons RL, Tsung A. Surgery for Cancer: A Trigger for Metastases. Cancer Res 2017;77:1548-1552.
  4. Verma V, Simone CB 2nd. Stereotactic body radiation therapy for metastases to the kidney in patients with non-small cell lung cancer: a new treatment paradigm for durable palliation. Ann Palliat Med 2017;6:96-103.
  5. Niu FY, Zhou Q, Yang JJ, Zhong WZ, Chen ZH, Deng W, et al. Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer 2016;16:149.
  6. Karagkiouzis G, Koulaxouzidis G, Tomos P, Spartalis ED, Konstantinou F, Charpidou A, et al. Solitary metastasectomy in non-small cell lung cancer. J BUON 2012;17:712-718.
  7. Tomita M, Ayabe T, Chosa E, Nakamura K. Isolated Renal Metastasis from Non-Small-Cell Lung Cancer: Report of 2 Cases. Case Rep Surg 2015;2015:357481.
  8. Craig DJ, Nanavaty NS, Devanaboyina M, Stanbery L, Hamouda D, Edelman G, et al. The abscopal effect of radiation therapy. Future Oncol 2021;17:1683-1694.

Published

2023-06-07

Issue

Vol. 10 No. 7 (2023)

How to Cite

1.
Matini E, Yogaretnam T, Wilson CA, Power D. The changing face of lung cancer: oligometastatic renal metastasis post chemo-immunotherapy combination. EJCRIM [Internet]. 2023 Jun. 7 [cited 2026 Nov. 3];10(7). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3908